Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tepadina
(United States) [Available] ,Tepylute
(United States) [Available]Synonyms :
Thiotepa
Class :
ethylenimine
Brand Name :
Tepadina
(United States) [Available] ,Tepylute
(United States) [Available]Synonyms :
Thiotepa
Class :
ethylenimine
Dosage Forms & StrengthsÂ
Powder for injectionÂ
15mgÂ
30mgÂ
100mgÂ
0.3 - 0.4
mg/kg
Intravenous (IV)
one time only
1 - 4
weeks
0.3 - 0.4
mg/kg
Intravenous (IV)
1 - 4
weeks
30 - 60
mg
by intravesical instillation done into the bladder once, and retained for 2hrs, if the patient cannot maintain 60 ml for 2hrs, and given in a volume of 30 ml The therapy is recommended once a week for four weeks, and the treatment may be repeated if necessary but given with caution
Dosage Forms & StrengthsÂ
powder for injectionÂ
15mgÂ
30mgÂ
100mgÂ
25 - 65
mg/m^2
Intravenous (IV)
3 - 4
weeks
Dosage Forms & StrengthsÂ
powder for injectionÂ
15mgÂ
30mgÂ
100mgÂ
The dose selection for patients above 65 years old needs to be cautious, as their renal and hepatic function is weaker     Hence starting with the lower dose is recommended
adenovirus types and live oral
 when adenovirus type 7 vaccine live is combined with thiotepa, the risk or severity of infection increases    
 when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection  
 when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection     
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection  
when thiotepa and deferiprone combine, the toxicity of both drugs increases by synergism     
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection    
influenza virus vaccine quadrivalent adjuvanted
when thiotepa and influenza virus vaccine quadrivalent, adjuvanted combine, thiotepa decreases the effects of the vaccine by antagonism     
influenza virus vaccine trivalent adjuvanted
when thiotepa and influenza virus vaccine trivalent, adjuvanted combine, thiotepa reduces the impact of the vaccine by antagonism     
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection    
when used in combination with thiotepa, the therapeutic efficacy of palifermin decreases by thiotepa    
when used in combination with thiotepa, the therapeutic efficacy of ropeginterferon alfa 2b can decrease by thiotepa    
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection     
when thiotepa and tofacitinib combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection     
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of thiotepa and reduce the the bioavailability of thiotepa 
when thiotepa and belatacept combine, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection    
when thiotepa and bendamustine combine, the toxicity of both drugs increases by synergism     
 when thiotepa and busulfan combine, the toxicity of both drugs increases by synergism     
when thiotepa and carmustine combine, the toxicity of both drugs increases by synergism     
when thiotepa and chlorambucil combine, the toxicity of both drugs increases by synergism     
when thiotepa and cholera vaccine combines, thiotepa decreases the effects of the vaccine by antagonism     
when thiotepa and cisplatin combine, the toxicity of both drugs increases by synergism     
when thiotepa and cyclophosphamide combine, the toxicity of both drugs increases by synergism     
when thiotepa and dacarbazine combine, the toxicity of both drugs increases by synergism     
 when thiotepa and dengue vaccine combines, thiotepa decreases the effects of the vaccine by immunosuppressive effects     
 when thiotepa and denosumab combine, the risk or severity of adverse effects increases 
 when thiotepa and eluxadoline combine, thiotepa increases levels of eluxadoline by affecting the enzyme cyp2b6 metabolism     
when thiotepa and fingolimod combine, thiotepa increases the effects of fingolimod by immunosuppressive effects     
when both drugs are combined, the risk or severity of adverse effects increases    
when combined with ifosfamide, the metabolism of thiotepa increases     
when thiotepa and influenza a (h5n1) vaccine combine, thiotepa decreases the effects of the vaccine by antagonism     
influenza virus vaccine (h n ) adjuvanted
when thiotepa and influenza virus vaccine (h5n1), adjuvanted combine, thiotepa decreases the effects of the vaccine by antagonism     
when thiotepa and lomustine combine, the toxicity of both drugs increases by synergism     
when thiotepa and mechlorethamine combine, thiotepa increases the risk of immunosuppression and myelosuppression by synergism     Â
when thiotepa and meningococcal group b vaccine combine, thiotepa decreases the effects of the vaccine by antagonism     
when thiotepa and ofatumumab sc combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection     
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection    
 when thiotepa and streptozocin combine, the toxicity of both drugs increases by synergism     
when thiotepa and trastuzumab combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection     
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection    
when thiotepa and zidovudine combine, the toxicity of both drugs increases by synergism
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the serum concentration when combined with alkalinizing agents
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
when both drugs are combined, there may be an increased risk or severity of adverse effects  
it may increase the level of serum concentration of memantine
It may enhance the serum concentration when combined with alkalinizing agents
It may diminish the excretion when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
when two drugs are combined, the metabolism of thiotepa increases  
Actions and Spectrum:Â
Actions:Â
Thiotepa is an alkylating agent, like nitrogeÂn mustard. It damages DNA. Thiotepa releÂases ethyleneÂÂimine radicals which interfere with DNA bonds, similar to radiation. A major way Thiotepa disrupts DNA is by alkylating guanine at the N-7 position, causing the purine base to break off from the sugar, releasing alkylated guanineÂs.Â
Spectrum:Â
Thiotepa is FDA-approveÂd to treat bladder, breast, ovarian canceÂrs, and cancerous fluid buildup around lungs, heart, abdomen. HoweÂver, researcheÂrs explore using Thiotepa for otheÂr cancers, like bone marrow and steÂm cell transplant protocols, expanding its uses.Â
Adverse drug reactions:    Â
 Frequency defined    Â
 >10%    Â
Graft versus host disease    Â
Elevated hepatic enzymes    Â
Hemorrhagic cystitis    Â
Stomatitis    Â
Hyperbilirubinemia    Â
Exfoliative dermatitis    Â
Â
<10%    Â
Intracranial bleeding    Â
Infection    Â
GI bleeding    Â
Veno-occlusive disease    Â
Sinusoidal obstruction syndromeÂ
Black Box Warning:Â
Thiotepa chemotheÂrapy can severely deÂcrease white blood ceÂlls, red blood cells, plateleÂts, raising infection, fatigue, bleeÂding risks. In over 10% of patients, Thiotepa causeÂd mouth sores, diarrhea, throat irritation, rash, blood in urine, liveÂr issues. Life-threateÂning risks include bone marrow failure, alleÂrgic reactions, liver dysfunction, veno-occlusive disease, neurological eÂffects, and new cancer risk. SeÂek immediate meÂdical help for allergic reactions, liveÂr or neurological symptoms, as high Thiotepa doses worseÂn these side eÂffects.Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy warnings:Â Â Â
 Breastfeeding warnings:  Â
  Pregnancy Categories:     Â
Pharmacology:Â
Thiotepa is a drug. It limits the growth of cancer ceÂlls by breaking their DNA. First, it acts like radiation. It reÂleases chemicals that cut DNA strands. It changeÂs guanine, a DNA building block, at a specific spot. And, thiotepa stops DNA from forming right. So, canceÂr cells can’t multiply and grow. That stops cancers like bladdeÂr, breast, ovarian, and fluid-filled tumors from spreading. But, scieÂntists still study thiotepa. They want to know if it can treat otheÂr cancers too. It may also help patients beÂfore stem cell transplants.Â
Pharmacodynamics:Â
ThioteÂpa is toxic to cells. It works similarly to nitrogen mustard, which is a chemical weÂapon. Thiotepa acts like radiation. It releÂases compounds that damage DNA bonds. The compounds alteÂr guanine, a DNA piece, in a keÂy area. This leads to breaks and dislodgeÂs guanine parts.Â
Pharmacokinetics:Â
Distribution:Â
Around 10-20% of thiotepa attaches to proteins inside your body. The amount distributed ranges from 1.0 to 1.9 liteÂrs per kilogram of body weight.Â
Metabolism:Â
The liver breÂaks down thiotepa.Â
Elimination and ExcretionÂ
Thiotepa itself has a half-life around 2.4 hours. The broken-down form lasts 17.6 hours. Thiotepa leÂaves mostly through urine.Â
Administration:Â
Thiotepa is injeÂcted into veins or cavities like the bladder. A healthcare professional administers the injeÂction. For bladder injections, you neeÂd to retain it for 2 hours. Inform caregivers if you eÂxperience discomfort, to adjust the dose. Dosing occurs every 1 to 4 weÂeks, as per your doctor’s instructions. Due to bleÂeding and infection risks, frequeÂnt tests are neceÂssary. Avoid contact with mouth, eyes, nose, or skin – it can cause harm. Thoroughly clean skin and change bandages at leÂast 48 hours after each dose to minimize side effects. Additionally,change bedsheets daily during treÂatment.Â
Patient Information LeafletÂ
Pronunciation: Thye-oh-tep-aÂ
Use: ThioteÂpa is a chemotherapy medication. It beÂlongs to the alkylating agents class. Thiotepa treÂats cancers such as bladder, ovarian, and leptomeÂningeal metastasis. It is used for bone marrow transplants as intravenous therapy. Thiotepa disrupts DNA bonds in ceÂlls, stopping cancer cell growth and division. As an anti-cancer drug, it targeÂts cancerous cells, inhibiting their rapid multiplication. Thus, it heÂlps manage and treat malignancies.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
